These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21225940)

  • 1. Disappearance of minimal residual disease after the early withdrawal of immunosuppressants in a patient with juvenile myelomonocytic leukemia.
    Yanagisawa R; Matsuda K; Sakashita K; Nakazawa Y; Tanaka M; Saito S; Yoshikawa K; Kamijo T; Shiohara M; Koike K
    Pediatr Blood Cancer; 2011 Mar; 56(3):501-2. PubMed ID: 21225940
    [No Abstract]   [Full Text] [Related]  

  • 2. Graft versus leukemia effect against juvenile myelomonocytic leukemia after unrelated cord blood transplantation.
    Tanoshima R; Goto H; Yanagimachi M; Kajiwara R; Kuroki F; Yokota S
    Pediatr Blood Cancer; 2008 Mar; 50(3):665-7. PubMed ID: 17437289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved outcomes associated with hematopoietic stem cell transplantation for patients with juvenile myelomonocytic leukemia.
    Zhao Q; Mahadeo KM; Kapoor N; Abdel-Azim H
    Blood; 2015 Jul; 126(4):561-2. PubMed ID: 26206948
    [No Abstract]   [Full Text] [Related]  

  • 5. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.
    Bacigalupo A; Sormani MP; Lamparelli T; Gualandi F; Occhini D; Bregante S; Raiola AM; di Grazia C; Dominietto A; Tedone E; Piaggio G; Podesta M; Bruno B; Oneto R; Lombardi A; Frassoni F; Rolla D; Rollandi G; Viscoli C; Ferro C; Garbarino L; Van Lint MT
    Haematologica; 2004 Oct; 89(10):1238-47. PubMed ID: 15477210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regression of the tumor after withdrawal of cyclosporine in relapsed extranodal natural killer/T cell lymphoma following allogeneic hematopoietic stem cell transplantation.
    Kako S; Izutsu K; Oshima K; Sato H; Kanda Y; Motokura T; Chiba S; Kurokawa M
    Am J Hematol; 2007 Oct; 82(10):937-9. PubMed ID: 17663389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Progressive multifocal leukoencephalopathy in a patient with acute myeloid leukaemia after allogeneic hematopoietic-cell transplantation].
    Fernández-Ruiz M; de la Serna J; Ruiz J; López-Medrano F
    Enferm Infecc Microbiol Clin; 2011 Oct; 29(8):636-7. PubMed ID: 21696864
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunotherapy by allogeneic stem cell transplantation.
    Ringdén O
    Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-lasting complete remission in plasma cell leukemia after aggressive chemotherapy and CD34-selected autologous peripheral blood progenitor cell transplant: molecular follow-up of minimal residual disease.
    Sica S; Chiusolo P; Salutari P; Piccirillo N; Laurenti L; Ortu La Barbera E; Serra FG; Leone G
    Bone Marrow Transplant; 1998 Oct; 22(8):823-5. PubMed ID: 9827984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal post-remission therapy for flow-cytometry minimal residual disease positive adult patients with acute myeloid leukemia.
    Buccisano F; Maurillo L; Del Poeta G; Gattei V; Amadori S; Venditti A
    Haematologica; 2006 Dec; 91(12 Suppl):ELT14; author reply ELT15. PubMed ID: 17194674
    [No Abstract]   [Full Text] [Related]  

  • 11. Juvenile myelomonocytic leukemia with t(7;11)(p15;p15) and NUP98-HOXA11 fusion.
    Mizoguchi Y; Fujita N; Taki T; Hayashi Y; Hamamoto K
    Am J Hematol; 2009 May; 84(5):295-7. PubMed ID: 19338047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
    Wernstedt P; Brune M; Andersson PO; Gustavsson B; Stockelberg D; Wadenvik H
    Bone Marrow Transplant; 2002 Dec; 30(12):971-3. PubMed ID: 12476293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful immunotherapy in early relapse of acute myeloid leukemia after nonmyeloablative allogeneic stem cell transplantation.
    Prinz E; Keil F; Kalhs P; Mitterbauer M; Rabitsch W; Rosenmayr A; Moser K; Schulenburg A; Lechner K; Greinix HT
    Ann Hematol; 2003 May; 82(5):295-8. PubMed ID: 12679886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Molecular mechanism and treatment of juvenile myelomonocytic leukemia (JMML)].
    Manabe A
    Rinsho Ketsueki; 2012 Aug; 53(8):729-33. PubMed ID: 22975811
    [No Abstract]   [Full Text] [Related]  

  • 15. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia.
    Brown JR; Kim HT; Li S; Stephans K; Fisher DC; Cutler C; Ho V; Lee SJ; Milford EL; Ritz J; Antin JH; Soiffer RJ; Gribben JG; Alyea EP
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1056-64. PubMed ID: 17084369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of both cords nine months post double cord blood transplantation for juvenile myelomonocytic leukaemia.
    Yadav SP; Dhingra N; Saxena R; Sachdeva A
    Hematol Oncol Stem Cell Ther; 2013 Jun; 6(2):79-80. PubMed ID: 23669498
    [No Abstract]   [Full Text] [Related]  

  • 17. Preemptive treatment of minimal residual disease post transplant in CML using real-time quantitative RT-PCR: a prospective, randomized trial.
    Kim YJ; Kim DW; Lee S; Chung NG; Hwang JY; Kim YL; Min CK; Kim CC
    Bone Marrow Transplant; 2004 Mar; 33(5):535-42. PubMed ID: 14716340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular assessment of pretransplant chemotherapy in the treatment of juvenile myelomonocytic leukemia.
    Hecht A; Meyer J; Chehab FF; White KL; Magruder K; Dvorak CC; Loh ML; Stieglitz E
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27948. PubMed ID: 31347788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning for adult T cell leukemia/lymphoma: impact of antithymocyte globulin on clinical outcome.
    Tanosaki R; Uike N; Utsunomiya A; Saburi Y; Masuda M; Tomonaga M; Eto T; Hidaka M; Harada M; Choi I; Yamanaka T; Kannagi M; Matsuoka M; Okamura J
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):702-8. PubMed ID: 18489996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor leukocyte transfusions and discontinuation of immunosuppressants to achieve an initial remission after allogeneic bone marrow transplantation in a patient with primary refractory acute leukemia.
    Azuno Y; Kaneko T; Nishimura M; Okuya S; Nakai K; Nomiyama J; Mori K; Okafuji K; Okubo M; Matsutani A; Kamei S; Zaitsu Y; Takeuchi Y; Oka Y; Kaku K
    Bone Marrow Transplant; 1996 Jul; 18(1):257-9. PubMed ID: 8832032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.